Cite
HARVARD Citation
Tapete, G. et al. (2022). Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases. Inflammatory bowel diseases. 28 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tapete, G. et al. (2022). Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases. Inflammatory bowel diseases. 28 (1), p. . [Online].